Billings Steven D, McKenney Jesse K, Folpe Andrew L, Hardacre Michael C, Weiss Sharon W
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Am J Surg Pathol. 2004 Jun;28(6):781-8. doi: 10.1097/01.pas.0000126055.33916.0b.
Iatrogenic angiosarcomas (AS), following treatment of breast carcinomas and attributed to chronic lymphedema, were first described by Stewart and Treves. With emphasis on breast-conserving therapy combined with adjuvant radiation, a recently recognized form of cutaneous postradiation angiosarcoma of the breast (CPRASB) has emerged. To more completely characterize CPRASB, 27 cases were analyzed. Histologic features studied included pattern of growth (vasoformative, sieve-like, or solid), nuclear grade, necrosis, and mitotic rate. Clinical and follow-up information was obtained. The patients received relatively standard radiation treatment. The median interval to diagnosis of CPRASB was 59 months; 5 occurred in less than 3 years. Lymphedema was largely absent, and when present was only mild in nature. CPRASB was frequently multifocal at presentation (13 of 27). All tumors had a vasoformative pattern of growth; the majority (16 of 27) had areas with a sieve-like pattern. The solid pattern was less frequent (7 of 27). The majority had high-grade nuclear features (16 grade 3, 8 grade 2, 3 grade1). The mean mitotic rate was 9/10 HPF. Necrosis was rare (2 of 27). All were treated with wide excision or mastectomy. Follow-up was available on 22 of 27 cases (median 44 months). Fourteen experienced local recurrence and 6 had multiple recurrences. Metastasis was documented in 9 of 22 patients and involved lungs (6), contralateral breast (3), skeleton (2), lymph nodes (1), and soft tissue (1). Eight patients died of disease, 2 died with disease, 4 were alive with disease, and 8 are alive without disease. The median interval to death was 33.5 months. All 4 patients with disease have documented metastasis. CPRASB differs from Stewart-Treves AS by its shorter latency period and lack of association with lymphedema.
医源性血管肉瘤(AS)是在乳腺癌治疗后因慢性淋巴水肿引起的,最早由斯图尔特和特里夫斯描述。随着对保乳治疗联合辅助放疗的重视,一种最近才被认识的乳腺皮肤放疗后血管肉瘤(CPRASB)出现了。为了更全面地描述CPRASB,对27例病例进行了分析。研究的组织学特征包括生长模式(血管形成型、筛状或实性)、核分级、坏死和有丝分裂率。获取了临床和随访信息。患者接受了相对标准的放射治疗。CPRASB的诊断中位间隔时间为59个月;5例发生在不到3年的时间内。淋巴水肿大多不存在,即使存在也只是轻度的。CPRASB在初诊时常常是多灶性的(27例中有13例)。所有肿瘤均具有血管形成型生长模式;大多数(27例中有16例)有筛状模式的区域。实性模式较少见(27例中有7例)。大多数具有高级别核特征(16例为3级,8例为2级,3例为1级)。平均有丝分裂率为9/10高倍视野。坏死罕见(27例中有2例)。所有患者均接受了广泛切除或乳房切除术。27例中有22例有随访资料(中位时间44个月)。14例出现局部复发,6例有多次复发。22例患者中有9例记录有转移,转移部位包括肺(6例)、对侧乳房(3例)、骨骼(2例)、淋巴结(1例)和软组织(1例)。8例患者死于疾病,2例带瘤死亡,4例带瘤生存,8例无瘤生存。死亡的中位间隔时间为33.5个月。所有4例带瘤患者均记录有转移。CPRASB与斯图尔特 - 特里夫斯血管肉瘤不同,其潜伏期较短且与淋巴水肿无关。